AzTrials
AzTrials

Atrial Fibrillation (AF)HOPE-AFNCT07178691

A Precision Medicine Approach to the Prevention of Depression in Patients With Atrial Fibrillation

A study testing Online psychological intervention in people with Atrial Fibrillation (AF) and Depression - Major Depressive Disorder, run by University of Southern Denmark at 3 sites in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the proposed project is to test a new therapist-assisted, eHealth intervention (HOPE-AF) targeted to prevent depression in patients with atrial fibrillation (AF). AF is the most common sustained cardiac arrhythmia. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Online psychological intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
28 participants
Where
3 sitesDenmark
Study dates
19 Apr 2024to 17 Mar 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years
  • Diagnosis of paroxysmal or persistent AF [if persistent AF, duration < 2 years]
  • Able to use and access a computer or tablet/iPad to adhere to the intervention - Proficient in the Danish language (reading and writing)
  • Ability to provide informed written consent.

Who cannot join

  • Depression [Hospital Anxiety and Depression Scale: HADS-D ≥11 (moderate symptoms)
  • Anxiety [Hospital Anxiety and Depression Scale: HADS-A ≥11 (moderate symptoms)
  • Severe psychiatric or neurological disorder (e.g., schizophrenia or dementia)
  • In need of psychiatric help due to comprehensive psychiatric issues, diagnosed or not
  • Seeing a psychologist or mental health professional for the treatment of depression and anxiety
  • Experiencing significant life stressors that hinder adherence to the HOPE-AF treatment
  • Participating in another research project involving intervention for depression
  • Not being able or willing to spend 1-2 hours on the intervention each week

Trial locations and contacts

3 sites in 1 country.

Denmark3 sites
  • Aalborg University Hospital

    Aalborg, 9100

  • University Hospital Esbjerg and Grindsted, University of Southern Denmark

    Esbjerg, 6700

  • Zealand University Hospital, Roskilde, Department of Cardiology

    Roskilde, 4000

Other trials in Denmark

About this study

Official title: A Precision Medicine Approach to the Prevention of Depression in Patients With Atrial Fibrillation - HOPE-AF

The purpose of the proposed project is to test a new therapist-assisted, eHealth intervention (HOPE-AF) targeted to prevent depression in patients with atrial fibrillation (AF). AF is the most common sustained cardiac arrhythmia. Age is the most common risk factor for AF, and given the ageing of the population, the prevalence of AF has increased threefold during the last 50 years. AF is now considered a major public health challenge. AF is not only associated with increased risk of stroke and heart failure but patients with AF also tend to continuously focus on the body's signals and have difficulties accepting the disease. This is often paired with psychological reactions, such as excessive worry and anxiety, increasing the risk of withdrawal from social activities, which often leads to depression. Patients with AF and comorbid depression are at greater risk of a poor prognosis.

The project is a feasibility study to examine acceptability, adherence and limited efficacy, as well as barriers and facilitators for implementation of the intervention in clinical practice. The project is multi-disciplinary and embedded within the rehabilitation setting in the hospitals, enhancing the chance of later implementation.

Read the detailed description

HOPE-AF represents a novel and pioneering approach to improving the HRQoL and prognosis of patients with AF through the prevention of depression, a seminal and debilitating risk factor for the onset of AF and worsening AF prognosis. Together with patients, the investigators co-designed an online psychological intervention that targets risk factors for depression with respect to preventing depression.

The feasibility of the intervention in clinical practice will be assessed. The intervention will be delivered via a GDPR-secured platform. This is an innovative solution for care delivery, enabling patients to access the intervention anytime, which may enhance adherence due to the flexibility of access and delivery. The investigators has previously shown that this eHealth mode of delivery is well received by patients.

Meta-analyses show that online psychological interventions are effective in preventing depression and anxiety in both at-risk cohorts and the general population. These positive effects have been shown for the cognitive-behavioral, interpersonal, and positive psychology therapeutic approaches.

The HOPE-AF intervention Recent research demonstrates that personalizing the prevention of depression by targeting individual risk factors for the disorder in every single patient can optimize treatment outcomes. HOPE-AF will specifically target and remediate the core risk factors for depression of each enrolled individual patient (i.e., stress, loneliness, social isolation, anhedonia, lack of exercise, low self-esteem, rumination, anxiety and sleep problems), using existing evidence-based treatments and a precision medicine approach to prevent depression.

The intervention is co-developed with patients and health professional and targeted to AF patients without current depression and anxiety. The intervention modules consist of psychoeducation, psychological tools, psychological therapies targeted to patients' risk factors for depression, and multimedia contents and exercises. Patients will complete the modules online and be assisted by a therapist who will provide feedback through asynchronous text messages via a GDPR secured platform. Phone or video (according to patients´ preferences) consultations with the therapist as add-on to the online intervention will be possible on a need to basis. The treatment duration will vary from patient to patient depending on the prevalent risk factors for depression and the severity of the risk factors. The duration will range from 4-12 weeks, as some modules will be mandatory for all patients, while other modules will only be relevant to target specific risk factors. Patients are expected to spend 1-2 hours per week on a module.

The HOPE-AF intervention is based on several different forms of evidence-based psychotherapies, including Cognitive Behavioral Therapy (CBT), Metacognitive Therapy (MCT), Acceptance and Commitment Therapy (ACT), Compassion Focused Therapy (CFT), Existential Therapy, Mindfulness, Interpersonal Therapy (IPT) and YOGA with psychological components. The included therapies allow for the most effective and comprehensive way of "treating" each specific risk factor for depression in each individual patient, with respect to patients' needs and preferences. Therapists also administer the CORE-10 questionnaire to patients every week during the intervention to evaluate progress. In case of deterioration, a contingency plan as written into the treatment protocol will be implemented that includes e.g., more frequent contact, more tailoring to meet patients' needs, suicidal risk assessment, and if relevant referral to the patient's GP. If patients become ill or leave on holidays during the intervention, the duration of the intervention will be extended with up to three weeks.

OBJECTIVES AND HYPOTHESES The overall purpose of HOPE-AF is to prevent depression and improve the health outcomes of patients with AF.

Specific objectives of the HOPE-AF feasibility study are to:

  • Assess the feasibility of the HOPE-AF intervention, with respect to acceptability and adherence, limited efficacy and patient retention (barriers and facilitators).
  • To test procedures with respect to recruitment and implementation in clinical practice.

INCLUSION Eligible patients will be included from cardiac units at hospitals. Patients are screened for symptoms of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS) questionnaire (range 0-21 for depression and anxiety respectively with increasing score reflecting more symptoms). Patients with HADS-D ≥11 or HADS-A ≥11, [which is considered a clinically significant level of symptoms] will be excluded from the study, since this a prevention initiative and not treatment. Eligible patients will receive the baseline questionnaire. Patients who do not complete the questionnaire within 30 days, will be excluded.

After completion of the baseline questionnaire, patients will be subjected to a brief standardized telephone interview by a member of the HOPE-AF team to further check for eligibility. The interview will be used to confirm patients´ motivation for participation, assess if patients have reading/writing abilities and internet literacy enabling adherence to the intervention, assess if patients are able to spend 1-2 hours on the intervention each week, and to assess if other life circumstances (e.g., present somatic health problems or other stressors in their personal life) make it impossible to adhere sufficiently to the intervention, and to exclude patients with a need for psychiatric help due to comprehensive psychiatric issues or major psychopathology. If patients answer yes to at least 1 of 3 purpose-designed questions to screen for suicidal ideation in the baseline questionnaire, the psychologist will make further assessments to determine if the patient requires psychiatric treatment.

To determine present risk factors for depression, eligible patients will receive a diagnostic interview by their assigned therapist. The presence or absence of risk factors for depression will determine the length and content of the HOPE-AF intervention.

DATA Given the general purpose of the feasibility study to examine barriers and facilitators related to the intervention and later successful implementation, the investigators will primarily use descriptive statistics (e.g., frequencies, percentages, means, ranges, and standard deviations) to analyse the patients pre-post outcome data and to estimate recruitment and data retention rate. The collected outcome measures are described elsewhere.

The feasibility study will also include interviews post-intervention with a sample of 10 participants, using semi-structured interviews related to their experiences with the intervention and procedures. The interview guide includes questions related to patient satisfaction, acceptance of the intervention, and barriers and facilitators for later implementation in clinical practice at a patient and organizational level. Interviews will be transcribed and analyzed using thematic analysis.

Being tested
Online psychological intervention
Keywords
atrial fibrillation, prevention of depression, Psychological intervention, online intervention
Medical subject headings
Atrial Fibrillation, Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Online psychological interventionOther

    The HOPE-AF intervention is an online psychological intervention to prevent depression in patients with atrial fibrillation. The intervention combines verbal psychological sessions over phone or video with online text messages and a tailored 4-12 weeks online intervention with new modules each week including psychological exercises in writing and as sound exercises (e.g., breathing exercises and relaxations exercises etc.) and videos.

Study groups in NCT07178691
Study groupRoleWhat they receive
online psychological interventionExperimentalThe participants will receive the HOPE-AF online psychological intervention. The intervention is designed to prevent depression in patients with atrial fibrillation
Receives: Other: Online psychological intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Drop out rate

    Drop out rate. What is the rate of drop out during the intervention from the 28 included patients. Drop out is defined as patients who want to stop the intervention or patients who stop responding to messages and phone/video calls. A drop-out rate <25% was considered acceptable.

    Measured: From start of the intervention to completion of intervention, i.e., from 0 to 12 weeks.

Secondary outcomes (7)
  1. Adherence

    The rate of completion of the assigned modules. Each module was labelled completed or non-completed. Completion of each module was defined as having completed tasks in the module and communicated with the therapist about the content.

    Measured: From start of the intervention to completion of intervention, i.e., from 0 to 12 weeks.

  2. Symptoms of depression

    Mean change score from baseline to follow-up on Depression (Hospital Anxiety and Depression Scale) (HADS-D). Range from 0-21 with higher score indicating more symptoms.

    Measured: From completion of baseline questionnaire (after enrollment and prior to intervention start) to completion of follow up questionniare (sent to patients 13 weeks after intervention start).

  3. Anxiety related to cardiac disease

    Mean change score of Anxiety related to cardiac disease (Cardiac Anxiety Questionnaire (CAQ)) from baseline to follow-up.

    CAQ comprises 18 items and can be divided in three subscales (Fear, 8 items; Avoidance, 5 items; Attention, 5 items). Each item is scored from 0 (never) to 4 (always). Higher score indicates greater number of symptoms or greater frequency. The total score is divided by the number of items, making the score range from 0 to 4 for each subscale and the total score.

    Measured: From completion of baseline questionnaire (after enrollment and prior to intervention start) to completion of follow up questionniare (sent to patients 13 weeks after intervention start).

  4. Symptoms of anxiety

    Mean change score of Anxiety from baseline to follow-up:

    Anxiety (Hospital Anxiety and Depression Scale) (HADS-A). Range from 0-21 with higher score indicating more symptoms.

    Measured: From completion of baseline questionnaire (after enrollment and prior to intervention start) to completion of follow up questionniare (sent to patients 13 weeks after intervention start).

  5. Atrial fibrillation related quality of life

    Mean change score from baseline to follow-up on: Atrial Fibrillation Effect on QualiTy-of-life Questionnaire (AFEQT) including total score and subscales (symptoms, daily activities, treatment concern). Total score and subscales range from 0-100 with higher score indicating better score.

    Measured: From completion of baseline questionnaire (after enrollment and prior to intervention start) to completion of follow up questionniare (sent to patients 13 weeks after intervention start).

  6. AF symptom burden

    Mean change score from baseline to follow-up on: AF symptom burden (AF-6). Range from 0-60 with higher score indicating worse outcome.

    Measured: From completion of baseline questionnaire (after enrollment and prior to intervention start) to completion of follow up questionniare (sent to patients 13 weeks after intervention start).

  7. Health related Quality of Life

    Mean change score from baseline to follow-up on: Health related Quality of Life (HeartQoL quesionnaire). The HeartQoL questionnaire is a 14-item questionnaire consisting of a Global scale [14 items] made up of Physical [10 items] and Emotional [4 items] subscales. Each subscore ranges from 0-3, a higher score indicating better outcome.

    Measured: From completion of baseline questionnaire (after enrollment and prior to intervention start) to completion of follow up questionniare (sent to patients 13 weeks after intervention start).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Sep 2025
  2. Study start19 Apr 2024
  3. Primary completion17 Mar 2025
  4. Study completion17 Mar 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
28 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07178691
Sponsor's protocol ID
12.048
Other IDs
S-20230078
Acronym
HOPE-AF
Status last verified
Apr 2026
First submitted
26 Aug 2025
Last updated
29 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Online psychological intervention in people with Atrial Fibrillation (AF) and Depression - Major Depressive Disorder, run by University of Southern Denmark at 3 sites in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Drop out rate (time frame: From start of the intervention to completion of intervention, i.e., from 0 to 12 weeks.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in